Literature DB >> 16874643

Surgical site infection (SSI) rates among patients who underwent mastectomy after the introduction of SSI prevention policies.

Diana Vilar-Compte1, Rodrigo Roldán-Marín, Carlos Robles-Vidal, Patricia Volkow.   

Abstract

OBJECTIVE: To describe the results of an intervention program to reduce the rate of surgical site infection (SSI) in the breast tumor department of a referral teaching hospital for patients with cancer.
METHODS: Preventive measures introduced in the Breast Tumor Department of the study hospital included the following: starting in July 2000, use of sterile technique for wound care; starting in 2001, use of closed antireflux silicone evacuation systems, use of perioperative antimicrobial prophylaxis, provision of feedback to surgeons, and remodeling of the ambulatory wound care clinic. We conducted surveillance of all patients who underwent mastectomy between February 1 and December 31, 2001, and the SSI rate was calculated. A case-control analysis was performed for risk factors known to be associated with SSI. Results were compared with the data from 2000.
RESULTS: The study included data on 385 surgeries. SSIs were registered in 52 (13.7%) of these 385, which was a rate 58.6% less than the 2000 infection rate (33.1%). Risk factors associated with SSI included concomitant chemotherapy and radiation therapy (OR, 3.6 [95% confidence interval {CI}, 1.9-7.1]), surgery performed during an evening shift (OR, 1.9 [95% CI, 1.1-3.6]), and insertion of a second drainage tube during the late postoperative period (OR, 2.8 [95% CI, 1.4-5.7]). The mean number (+/- SD) of postoperative visits to the outpatient wound care clinic was reduced from 11.6+/-7.1 in 2000 to 9.2+/-4.4 in 2001 (P<.001, Student's t test). The mean number of days that the evacuation systems were used was reduced from 19.0 to 16.0 days (P=.001, Student's t test).
CONCLUSIONS: Continuous wound surveillance, along with feedback to surgeons, use of closed antireflux evacuation systems, and standardized practices in wound and drainage-tube care, decreased by 58.6% the rate of SSI in a breast surgical department with high rates of infection.

Entities:  

Mesh:

Year:  2006        PMID: 16874643     DOI: 10.1086/506395

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  Surveillance and Prevention of Surgical Site Infections in Breast Oncologic Surgery with Immediate Reconstruction.

Authors:  Margaret A Olsen; Katelin B Nickel; Ida K Fox
Journal:  Curr Treat Options Infect Dis       Date:  2017-05-11

2.  Postoperative Day 1 Glucose May Be Associated With Wound Complications in Sarcomas Treated With Preoperative Radiation.

Authors:  Meena Bedi; David M King; Carlos Mendez; Barbara Slawski; John A Charlson; Donald A Hackbarth; John C Neilson
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

Review 3.  Surgical site infections in older adults: epidemiology and management strategies.

Authors:  Michael H Young; Laraine Washer; Preeti N Malani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Surgical site infection among women discharged with a drain in situ after breast cancer surgery.

Authors:  Wilza Andrade Barbosa Felippe; Guilherme Loureiro Werneck; Guilherme Santoro-Lopes
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

5.  Dressing Wear Time after Breast Reconstruction: A Randomized Clinical Trial.

Authors:  Daniela Francescato Veiga; Carlos Américo Veiga Damasceno; Joel Veiga-Filho; Luiz Francisley Paiva; Fernando Elias Martins Fonseca; Isaías Vieira Cabral; Natália Lana Larcher Pinto; Yara Juliano; Lydia Masako Ferreira
Journal:  PLoS One       Date:  2016-12-02       Impact factor: 3.240

6.  Antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial.

Authors:  Edgard Silva Garcia; Daniela Francescato Veiga; Joel Veiga-Filho; Isaías Vieira Cabral; Natália Lana Larcher Pinto; Neil Ferreira Novo; Miguel Sabino Neto; Lydia Masako Ferreira
Journal:  Trials       Date:  2016-11-30       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.